
Pharmacists explore new breast cancer therapies and management strategies, enhancing patient care and treatment outcomes at SABCS.

Pharmacists explore new breast cancer therapies and management strategies, enhancing patient care and treatment outcomes at SABCS.

Ribociclib shows higher early treatment modifications than palbociclib in HR+/HER2– breast cancer, emphasizing the need for proactive toxicity management.

Heidi De Souza, MPH, reveals low RSV vaccine uptake among older adults, highlighting disparities and barriers that hinder access and awareness post-FDA approval.

The approval offers hope for improved lung function and new treatment options for patients.

Serotypes included in the pneumococcal 21-valent conjugate vaccine (PCV21) cause outsized disease and economic burden in Norwegian patients with pneumococcal disease.

Lessons learned from interprofessional spiritual training and the evolving role of palliative care pharmacists toward an integrated and patient-centric health care system.

Oncology pharmacists and the pharmaceutical industry can enhance patient care through improved support, education, and access to innovative treatments.

COVID-19 vaccination significantly lowers severe illness and preterm birth risks for pregnant individuals.

The most impactful FDA approvals of 2025 feature groundbreaking treatments for mental health, STIs, diabetes, pain relief, and cardiovascular health.

A technician-driven workflow implemented in a health system’s specialty pharmacy reduced high-cost oncology drug waste.

Explore essential supplement recommendations for older adults, including vitamin D, calcium, melatonin, and multivitamins, to enhance health and well-being.

New agreements aim to align US drug prices with European standards, enhancing Medicaid savings and enabling direct consumer purchases.

Research highlights the critical link between chronic kidney disease (CKD) and uncontrolled gout, emphasizing a need for enhanced awareness and treatment strategies.

FDA approves Fesilty, a new fibrinogen concentrate, offering hope for effective treatment of congenital fibrinogen deficiency and acute bleeding episodes.

New clinical trial results highlight the effectiveness of enfortumab vedotin and pembrolizumab in improving survival for patients with muscle-invasive bladder cancer.

Pharmacy technicians enhance safety and efficiency in hazardous drug compounding.

The rise of intravesical therapies in non–muscle invasive bladder cancer underscores the vital role of pharmacists in advancing patient care.

GLP-1 medications show promise in reducing chemotherapy side effects and improving heart health in breast cancer patients, warranting further research.

Pharmacists are crucial in combating opioid use disorder, enhancing treatment options, and reducing drug overdose deaths linked to fentanyl.

A UK research team has pioneered a blood test using infrared technology to detect lung cancer cells, promising earlier diagnoses and personalized treatments.

Community pharmacists are crucial in Increasing immunization rates, addressing access barriers, and supporting evidence-based immunization guidance.

Clinicians learn to optimize type 2 diabetes treatment using automated insulin delivery data, enhancing patient safety and education for effective management.

FDA approves Rybrevant Faspro, a groundbreaking subcutaneous therapy for EGFR-mutated lung cancer, enhancing patient comfort and survival rates.

The approval was supported by findings from the TRITON3 trial, which enrolled certain patients with metastatic castration-resistant prostate cancer (mCRPC).

Pharmacists can educate patients about FluMist for at-home administration and opioid labeling changes.

Experts discuss innovations in medication-use processes at the ASHP Midyear Meeting, highlighting trends in acute and ambulatory care for pharmacy leaders.

Patients learn the importance of understanding treatment-related skin issues, recognizing symptoms, and adopting gentle skincare practices for better management.


This review examines the mechanisms of therapy, summarizes the existing literature, and highlights the evolving treatment options for unresectable hepatocellular carcinoma.

Findings from a meta-analysis reveal biosimilars for inflammatory bowel disease (IBD) offer similar efficacy and safety and maintained remission rates as their reference products.